H.C. Wainwright Global Life Sciences Conference, London, UK – cancelled

GenSight Biologics Provides Update on Operations in the Context of COVID-19

GenSight Biologics Reports Full Year 2019 Financial Results and provides an Outlook on 2020

GenSight Biologics Reports its Cash Position as of December 31, 2019 and Provides Operational Update

GenSight Biologics Announces its 2020 Financial Calendar

GenSight Biologics Announces the Filing of its 2018 Universal Registration Document

GenSight Biologics obtains €15 million in financing through a bond issuance from Kreos Capital and a reserved capital increase from Sofinnova and 3SBio

GenSight Biologics Reports its Cash Position as of September 30, 2019 and Provides Operational Update

GenSight Biologics integrates the Enternext® PEA-PME 150 index by Euronext

GenSight Biologics Reports Interim Financial Results for the First Half of 2019 and Provides Operational Update